#OP0223 at #EULAR2026: Not every lupus nephritis patient may need upfront triple therapy. Using EULAR 2025 prognostic factors, triple therapy significantly improved complete renal response only in high-risk patients, supporting more precision-based treatment approach. @RheumNow https://t.co/F8Kn23YjNr

• https://x.com/DrMiniDey/status/2062448268018364684/photo/1

Ivarmacitinib (selective oral JAKi) in active nr-axSpA: This ph3 RCT showed that Ivarmacitinib 4mg significantly improved s/sxs & dse act vs. PBO at wk 12 (39.7% vs 24.8%; P=0.0057) and maintained until wk 24 Interesting. A new JAKi option for axSpA OPO237 @RheumNow #EULAR2026 https://t.co/bxbO8GfegP

• https://x.com/RHEUMarampa/status/2062447326711463952/photo/1
• https://x.com/RHEUMarampa/status/2062447326711463952/photo/1

#OP0222 at #EULAR2026: ReBioLup highlights the disconnect between proteinuria & histopathological activity in lupus nephritis. 73% of patients with persistent histologic activity at 12 months still met criteria for complete clinical response. @RheumNow https://t.co/VxgT6812VO

• https://x.com/DrMiniDey/status/2062446003274580081/photo/1

ASAS-SPARTAN revised #axSpA classification criteria have hug specificity (>94%) but lower sensitivity than the 2009 criteria, excluding ~27% of patients classified by the older criteria Abstr OP239 @RheumNow #EULAR2026 https://t.co/vGJN8eEKKh

• https://x.com/synovialjoints/status/2062445596154180070/photo/1

Mean disease duration in the tofacitinib arm was just 0.57 years since diagnosis. This is genuinely early #axSpA and JAK1 inhibition achieves near-remission rates above placebo. An oral option for early axSpA Abstr#0241 @RheumNow #EUlAR2026

#OP0219 at #EULAR2026: Real-world ASTER data suggest DORIS remission & LLDAS are achievable with anifrolumab in routine practice, assoc w ⬇️risk of organ damage accrual. Over 12m, 43% attained DORIS remission & 74% LLDAS. Low serious adverse event rates reported. @RheumNow

#EULAR2026 OP0216 With the advances in biologics/cell-based therapies in #SLE, we need to define “severe refractory.” Data-driven analysis from 13 nations suggested: SLEDAI≥6 + PGA>1 + mild-moderate or severe flare (MMSf) + GC≥10 +IS. Need validation study before use @RheumNow https://t.co/K2dMSQUIgB

• https://x.com/Yuz6Yusof/status/2062436505902096486/photo/1

#OP006 - Urine proteomics in LN tracks histo activity & treatment response better than proteinuria. Paired biopsies linked active disease to IFNI, IL12, complement & neut pathways- normalised in responders but persisted in non-responders. @RheumNow #EULAR2026 #EULARBest #Plenary

#EULAR2026 Please find my video interview with Prof Xavier Mariette, the presenting author of Abstract OP0126: Efficacy and Safety of Ianalumab in #Sjogren disease #SjD @RheumNow https://t.co/NEyBOD6Qj2 https://t.co/Zn1fH6eu39

• Efficacy and Safety of Ianalumab in Sjogren's Disease
• https://x.com/Yuz6Yusof/status/2062419072520749216/photo/1

💉 Is Izokibep (Novel IL-17i) durable in PsA at 1yr? Phase2b/3 RCT: ~50% ACR50 at week in 343pts OP073 #EULAR2026 @RheumNow https://t.co/M3nrKFTA7c

• https://x.com/Nellziade/status/2062265661829611550/photo/1

🔬 Does synovial biopsy-guided treatment outperform standard care in PsA? YES - 68% vs 45% DAPSA remission/LDA in 45pts OP071 #EULAR2026 @RheumNow https://t.co/cLCR7I8QAm

• https://x.com/Nellziade/status/2062264618098065814/photo/1

#Rosnilimab works!! #PD1 agonist In #moderate to severe #RA showed fast deep responses in Ph2 #PBO CONTROLLED #rheumatoid #athritis Seemed NOT to have sig side effects compared to some PD1 drugs that ceased development in RA #EULAR2026 @RheumNow #OP0202 #EULARbest https://t.co/Jz92npXdgd

• https://x.com/Janetbirdope/status/2062440115578777860/photo/1
• https://x.com/Janetbirdope/status/2062440115578777860/photo/1

SUNSTAR head-to-head after failure of 1 (80+%)–2 prior b/tsDMARDs in RA TCZ vs. ABA Confirms what we already knew: -Primary endpoint CDAI change wk26 not different -Composite response (persistence + low disease activity + low steroid use) 51% vs 35% p=0.034 -Better response in https://t.co/002n3sWtKs

• https://x.com/AurelieRheumo/status/2062447221258232281/photo/1
• https://x.com/AurelieRheumo/status/2062447221258232281/photo/1
• https://x.com/AurelieRheumo/status/2062447221258232281/photo/1
• https://x.com/AurelieRheumo/status/2062447221258232281/photo/1

Tofacitinib achieved ASDAS inactive disease in 26.4% of patients with early #axSpA (back pain ≤2 years) vs 7.4% placebo at 16 weeks (p=0.006). First RCT of advanced therapy in very early axSpA Abstr#0241 @RheumNow #EULAR2026

Day 2 of #EULAR2026 Studies to look forward today in #axSpA: new classification criteria performance, sex differences in disease progression, early disease treatment data, primary care education to reduce delays to diagnosis @RheumNow